{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:36:17Z","timestamp":1777354577705,"version":"3.51.4"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Polycythemia vera (PV) is a clonal myeloproliferative neoplasm (MPN) typically defined by JAK2 mutations. JAK2-negative presentations pose significant diagnostic challenges and likely harbor a spectrum of molecular drivers that remain incompletely characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a case of JAK2-negative PV-like MPN in a 53-year-old male presenting with erythrocytosis, suppressed erythropoietin, panmyelotic bone marrow morphology, and splenic vein thrombosis. Standard JAK2 V617F and exon 12 analyses were negative. Next-generation sequencing (NGS) identified a KMT2C nonsense variant (c.2961C&amp;gt;G, p.Tyr987*) at a variant allele frequency (VAF) of 21%, providing molecular evidence of clonality. The clinical course was complicated by intermittent hydroxyurea non-adherence with marked hematocrit fluctuations; dose optimisation from 1\u00a0g to 2\u00a0g daily achieved stable hematological control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case adds to the emerging molecular landscape of JAK2-negative MPNs by identifying KMT2C loss-of-function as a clonal marker in a patient with a JAK2-negative PV-like MPN phenotype. Whether KMT2C p.Tyr987* contributes causally to the erythroid-biased expansion or represents an accompanying clonal event warrants functional investigation. Comprehensive genomic profiling is essential when canonical driver mutations are absent, and strict adherence to cytoreductive targets remains critical to prevent thrombotic complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1825434","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:31:57Z","timestamp":1777350717000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A KMT2C loss-of-function mutation in a JAK2-negative polycythemia vera\u2013like myeloproliferative neoplasm: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Tala N.","family":"Musa","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Al-Quds University","place":["East Jerusalem, Palestine"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalal","family":"Al Khateeb","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Quds University","place":["East Jerusalem, Palestine"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousef","family":"Sajdieh","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Quds University","place":["East Jerusalem, Palestine"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasser M.","family":"Abualia","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Quds University","place":["East Jerusalem, Palestine"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akram","family":"Karama","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Quds University","place":["East Jerusalem, Palestine"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of hematolymphoid tumors: Myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.03.016","article-title":"MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia","volume":"25","author":"Chen","year":"2014","journal-title":"Cancer Cell"},{"key":"B6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-024-01590-1","article-title":"KMT2C mutations in acute myeloid leukemia: A multinational cohort study","volume":"17","author":"Halik","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1825434\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:32:17Z","timestamp":1777350737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1825434\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":12,"alternative-id":["10.3389\/fonc.2026.1825434"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1825434","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"article-number":"1825434"}}